Anjana Pillai, MD, University of Chicago Medicine Comprehensive Cancer Center

Advanced Biliary Tract Cancers: Managing Immunotherapy-Related Adverse Events

Milind Javle, MD, The University of Texas MD Anderson Cancer Center;Aiwu Ruth He, MD, PhD;Anjana Pillai, MD, University of Chicago Medicine Comprehensive Cancer Center;Flavio G. Rocha, MD, FACS, FSSO, Oregon Health & Science University;Mark Yarchoan, MD, Johns Hopkins Medicine

November 2nd 2022

Expert perspectives on the toxicity profile of immunotherapy agents and how they can be managed in patients being treated for advanced biliary tract cancers.

TOPAZ-1: Durvalumab + Doublet Chemotherapy in Advanced Biliary Tract Cancers

Milind Javle, MD, The University of Texas MD Anderson Cancer Center;Aiwu Ruth He, MD, PhD;Anjana Pillai, MD, University of Chicago Medicine Comprehensive Cancer Center;Flavio G. Rocha, MD, FACS, FSSO, Oregon Health & Science University;Mark Yarchoan, MD, Johns Hopkins Medicine

October 26th 2022

Centering their conversation on the TOPAZ-1 clinical trial, expert panelists review the use of IO + chemotherapy in advanced biliary tract cancers.

Treatment Options for Early-Stage Biliary Tract Cancers

Milind Javle, MD, The University of Texas MD Anderson Cancer Center;Aiwu Ruth He, MD, PhD;Anjana Pillai, MD, University of Chicago Medicine Comprehensive Cancer Center;Flavio G. Rocha, MD, FACS, FSSO, Oregon Health & Science University;Mark Yarchoan, MD, Johns Hopkins Medicine

October 5th 2022

Centering discussion on early-stage biliary tract cancers, expert panelists consider the respective roles of surgery and embolization strategies in this setting.

Guidelines for Molecular Testing in Biliary Tract Cancers

Milind Javle, MD, The University of Texas MD Anderson Cancer Center;Aiwu Ruth He, MD, PhD;Anjana Pillai, MD, University of Chicago Medicine Comprehensive Cancer Center;Flavio G. Rocha, MD, FACS, FSSO, Oregon Health & Science University;Mark Yarchoan, MD, Johns Hopkins Medicine

October 5th 2022

Panelists share their perspectives on molecular testing guidelines for patients diagnosed with biliary tract cancers.

Biliary Tract Cancers: Staging and Clinicopathologic Features

Milind Javle, MD, The University of Texas MD Anderson Cancer Center;Aiwu Ruth He, MD, PhD;Anjana Pillai, MD, University of Chicago Medicine Comprehensive Cancer Center;Flavio G. Rocha, MD, FACS, FSSO, Oregon Health & Science University;Mark Yarchoan, MD, Johns Hopkins Medicine

September 28th 2022

Comprehensive insight on staging biliary tract cancers followed by an overview of molecular testing and targetable clinicopathologic features.

Challenges in Diagnosing Biliary Tract Cancers

Milind Javle, MD, The University of Texas MD Anderson Cancer Center;Aiwu Ruth He, MD, PhD;Anjana Pillai, MD, University of Chicago Medicine Comprehensive Cancer Center;Flavio G. Rocha, MD, FACS, FSSO, Oregon Health & Science University;Mark Yarchoan, MD, Johns Hopkins Medicine

September 28th 2022

Expert perspectives on the presentation of biliary tract cancers with specific insight to the challenges inherent in reaching a timely diagnosis.

Incidence and Risk Factors for Biliary Tract Cancers

Milind Javle, MD, The University of Texas MD Anderson Cancer Center;Aiwu Ruth He, MD, PhD;Anjana Pillai, MD, University of Chicago Medicine Comprehensive Cancer Center;Flavio G. Rocha, MD, FACS, FSSO, Oregon Health & Science University;Mark Yarchoan, MD, Johns Hopkins Medicine

September 21st 2022

Shared insight on the global incidence of biliary tract cancers and which risk factors most impact the likelihood of disease.

An Overview on Biliary Tract Cancers

Milind Javle, MD, The University of Texas MD Anderson Cancer Center;Aiwu Ruth He, MD, PhD;Anjana Pillai, MD, University of Chicago Medicine Comprehensive Cancer Center;Mark Yarchoan, MD, Johns Hopkins Medicine;Flavio G. Rocha, MD, FACS, FSSO, Oregon Health & Science University

September 21st 2022

Opening their discussion on biliary tract cancers, a multidisciplinary panel of experts consider how specific subsets of these malignancies differ from one another.

Optimizing Precision Medicine in HCC

Tanios S. Bekaii-Saab, MD, FACP, Mayo Clinic;Edward Kim, MD, Mount Sinai Medical Center;Anjana Pillai, MD, University of Chicago Medicine Comprehensive Cancer Center;Amit Singal, MD, UT Southwestern Medical Center;Rachna Shroff, MD, University of Arizona;Arndt Vogel, MD, Hannover Medical School;Mark Yarchoan, MD, Johns Hopkins Medicine

October 1st 2021

Takeaways from a discussion on treatment advances in hepatocellular carcinoma.

Biomarkers to Guide HCC Treatment Decisions

Tanios S. Bekaii-Saab, MD, FACP, Mayo Clinic;Edward Kim, MD, Mount Sinai Medical Center;Anjana Pillai, MD, University of Chicago Medicine Comprehensive Cancer Center;Amit Singal, MD, UT Southwestern Medical Center;Rachna Shroff, MD, University of Arizona;Arndt Vogel, MD, Hannover Medical School;Mark Yarchoan, MD, Johns Hopkins Medicine

October 1st 2021

Professionals who treat patients with hepatocellular carcinoma comment on the need for more research and biomarkers to fuel treatment decisions.

Second-Line Treatment Approaches for Advanced HCC

Tanios S. Bekaii-Saab, MD, FACP, Mayo Clinic;Edward Kim, MD, Mount Sinai Medical Center;Anjana Pillai, MD, University of Chicago Medicine Comprehensive Cancer Center;Amit Singal, MD, UT Southwestern Medical Center;Rachna Shroff, MD, University of Arizona;Arndt Vogel, MD, Hannover Medical School;Mark Yarchoan, MD, Johns Hopkins Medicine

September 24th 2021

An overview of the second-line treatment landscape for patients with advanced hepatocellular carcinoma and considerations regarding the sequencing of novel therapies.

The COSMIC-312 Study in Advanced HCC

Tanios S. Bekaii-Saab, MD, FACP, Mayo Clinic;Edward Kim, MD, Mount Sinai Medical Center;Anjana Pillai, MD, University of Chicago Medicine Comprehensive Cancer Center;Amit Singal, MD, UT Southwestern Medical Center;Rachna Shroff, MD, University of Arizona;Arndt Vogel, MD, Hannover Medical School;Mark Yarchoan, MD, Johns Hopkins Medicine

September 24th 2021

Thoughts regarding the COSMIC-312 study of cabozantinib plus atezolizumab as frontline therapy for advanced hepatocellular carcinoma.

HCC: IO in Liver Transplant Recipients

Tanios S. Bekaii-Saab, MD, FACP, Mayo Clinic;Edward Kim, MD, Mount Sinai Medical Center;Anjana Pillai, MD, University of Chicago Medicine Comprehensive Cancer Center;Amit Singal, MD, UT Southwestern Medical Center;Rachna Shroff, MD, University of Arizona;Arndt Vogel, MD, Hannover Medical School;Mark Yarchoan, MD, Johns Hopkins Medicine

September 17th 2021

A debate regarding the appropriateness of immunotherapy following liver transplantation in patients with hepatocellular carcinoma.

The LEGACY Study in HCC

Tanios S. Bekaii-Saab, MD, FACP, Mayo Clinic;Edward Kim, MD, Mount Sinai Medical Center;Anjana Pillai, MD, University of Chicago Medicine Comprehensive Cancer Center;Amit Singal, MD, UT Southwestern Medical Center;Rachna Shroff, MD, University of Arizona;Arndt Vogel, MD, Hannover Medical School;Mark Yarchoan, MD, Johns Hopkins Medicine

September 17th 2021

Implications on treatment practices of the LEGACY study of Y-90 glass microspheres in patients with unresectable solitary hepatocellular carcinoma.

Selecting First-Line Therapy for Advanced HCC

Tanios S. Bekaii-Saab, MD, FACP, Mayo Clinic;Edward Kim, MD, Mount Sinai Medical Center;Anjana Pillai, MD, University of Chicago Medicine Comprehensive Cancer Center;Amit Singal, MD, UT Southwestern Medical Center;Rachna Shroff, MD, University of Arizona;Arndt Vogel, MD, Hannover Medical School;Mark Yarchoan, MD, Johns Hopkins Medicine

September 10th 2021

An overview of factors that deem patients appropriate for atezolizumab/bevacizumab vs lenvatinib or sorafenib as frontline therapy for advanced hepatocellular carcinoma.

Frontline IO for Advanced HCC

Tanios S. Bekaii-Saab, MD, FACP, Mayo Clinic;Edward Kim, MD, Mount Sinai Medical Center;Anjana Pillai, MD, University of Chicago Medicine Comprehensive Cancer Center;Amit Singal, MD, UT Southwestern Medical Center;Rachna Shroff, MD, University of Arizona;Arndt Vogel, MD, Hannover Medical School;Mark Yarchoan, MD, Johns Hopkins Medicine

September 10th 2021

Considerations regarding the use of nivolumab as frontline treatment for advanced hepatocellular carcinoma.

Systemic Treatment Advances for Advanced HCC

Tanios S. Bekaii-Saab, MD, FACP, Mayo Clinic;Edward Kim, MD, Mount Sinai Medical Center;Anjana Pillai, MD, University of Chicago Medicine Comprehensive Cancer Center;Amit Singal, MD, UT Southwestern Medical Center;Rachna Shroff, MD, University of Arizona;Arndt Vogel, MD, Hannover Medical School;Mark Yarchoan, MD, Johns Hopkins Medicine

September 3rd 2021

Exciting developments using novel therapies as systemic treatment for advanced hepatocellular carcinoma.

Scoring/Classifying Patients With Advanced HCC

Tanios S. Bekaii-Saab, MD, FACP, Mayo Clinic;Edward Kim, MD, Mount Sinai Medical Center;Anjana Pillai, MD, University of Chicago Medicine Comprehensive Cancer Center;Amit Singal, MD, UT Southwestern Medical Center;Rachna Shroff, MD, University of Arizona;Arndt Vogel, MD, Hannover Medical School;Mark Yarchoan, MD, Johns Hopkins Medicine

September 3rd 2021

Best practices using available scoring systems to evaluate and treat patients with advanced hepatocellular carcinoma.

Adjuvant Treatment Advances in Operable HCC

Tanios S. Bekaii-Saab, MD, FACP, Mayo Clinic;Edward Kim, MD, Mount Sinai Medical Center;Anjana Pillai, MD, University of Chicago Medicine Comprehensive Cancer Center;Amit Singal, MD, UT Southwestern Medical Center;Rachna Shroff, MD, University of Arizona;Arndt Vogel, MD, Hannover Medical School;Mark Yarchoan, MD, Johns Hopkins Medicine

August 27th 2021

Perspectives regarding treatment advances using adjuvant approaches that include immunotherapy to treat early-stage hepatocellular carcinoma.

Hepatic Arterial Infusion Chemotherapy for HCC

Tanios S. Bekaii-Saab, MD, FACP, Mayo Clinic;Edward Kim, MD, Mount Sinai Medical Center;Anjana Pillai, MD, University of Chicago Medicine Comprehensive Cancer Center;Amit Singal, MD, UT Southwestern Medical Center;Rachna Shroff, MD, University of Arizona;Arndt Vogel, MD, Hannover Medical School;Mark Yarchoan, MD, Johns Hopkins Medicine

August 27th 2021

Reactions to recent clinical abstracts that support the use of hepatic arterial infusions for chemotherapy delivery in hepatocellular carcinoma.

Neoadjuvant Therapy to Downstage HCC

Tanios S. Bekaii-Saab, MD, FACP, Mayo Clinic;Edward Kim, MD, Mount Sinai Medical Center;Anjana Pillai, MD, University of Chicago Medicine Comprehensive Cancer Center;Amit Singal, MD, UT Southwestern Medical Center;Rachna Shroff, MD, University of Arizona;Arndt Vogel, MD, Hannover Medical School;Mark Yarchoan, MD, Johns Hopkins Medicine

August 20th 2021

Reactions to treatment gaps in the neoadjuvant space for hepatocellular carcinoma and implications for incorporating data supporting newer, novel systemic therapies for appropriate patients.

Advances in Locoregional Therapy for Early Stage HCC

Tanios S. Bekaii-Saab, MD, FACP, Mayo Clinic;Edward Kim, MD, Mount Sinai Medical Center;Anjana Pillai, MD, University of Chicago Medicine Comprehensive Cancer Center;Amit Singal, MD, UT Southwestern Medical Center;Rachna Shroff, MD, University of Arizona;Arndt Vogel, MD, Hannover Medical School;Mark Yarchoan, MD, Johns Hopkins Medicine

August 20th 2021

University of Arizona’s Rachna Shroff, MD, describes the role of systemic therapy with locoregional treatment for early stage hepatocellular carcinoma and highlights treatment strategies of interest that remain under investigation.

Current Role of Locoregional Therapy for Early Stage HCC

Tanios S. Bekaii-Saab, MD, FACP, Mayo Clinic;Edward Kim, MD, Mount Sinai Medical Center;Anjana Pillai, MD, University of Chicago Medicine Comprehensive Cancer Center;Amit Singal, MD, UT Southwestern Medical Center;Rachna Shroff, MD, University of Arizona;Arndt Vogel, MD, Hannover Medical School;Mark Yarchoan, MD, Johns Hopkins Medicine

August 13th 2021

Edward Kim, MD, of Mount Sinai Health System describes where advances in locoregional therapy for early-stage hepatocellular carcinoma fit into the therapeutic landscape.